Buy Rating for Lipocine: Anticipation of Successful LPCN 1154 Study and Strong Financial Position
TipRanksNov 9, 2023 12:12 ET
Cantor Fitzgerald Reiterates Overweight on Lipocine, Maintains $33 Price Target
BenzingaJul 27, 2023 10:09 ET
Lipocine Analyst Ratings
BenzingaJul 27, 2023 10:07 ET
No Data